Lipocine, Inc. (LPCN)
1.615
+0.08
(+5.56%)
USD |
NASDAQ |
Nov 06, 10:25
Lipocine Net Income (Quarterly) : -2.623M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -2.623M |
| March 31, 2026 | -3.672M |
| December 31, 2025 | -2.370M |
| September 30, 2025 | -3.187M |
| June 30, 2025 | -2.206M |
| March 31, 2025 | -1.865M |
| December 31, 2024 | 1.782M |
| September 30, 2024 | -2.219M |
| June 30, 2024 | -3.069M |
| March 31, 2024 | 3.514M |
| December 31, 2023 | -2.282M |
| September 30, 2023 | -6.651M |
| June 30, 2023 | -3.549M |
| March 31, 2023 | -3.870M |
| December 31, 2022 | -2.230M |
| September 30, 2022 | -2.409M |
| June 30, 2022 | -2.632M |
| March 31, 2022 | -3.488M |
| December 31, 2021 | 12.62M |
| September 30, 2021 | -3.081M |
| June 30, 2021 | -6.809M |
| March 31, 2021 | -3.368M |
| December 31, 2020 | -4.511M |
| September 30, 2020 | -4.313M |
| June 30, 2020 | -6.370M |
| Date | Value |
|---|---|
| March 31, 2020 | -5.771M |
| December 31, 2019 | -3.292M |
| September 30, 2019 | -3.060M |
| June 30, 2019 | -3.431M |
| March 31, 2019 | -3.224M |
| December 31, 2018 | -3.226M |
| September 30, 2018 | -2.459M |
| June 30, 2018 | -3.256M |
| March 31, 2018 | -2.72M |
| December 31, 2017 | -5.332M |
| September 30, 2017 | -4.700M |
| June 30, 2017 | -6.090M |
| March 31, 2017 | -4.861M |
| December 31, 2016 | -2.966M |
| September 30, 2016 | -3.236M |
| June 30, 2016 | -5.760M |
| March 31, 2016 | -7.009M |
| December 31, 2015 | -4.634M |
| September 30, 2015 | -6.372M |
| June 30, 2015 | -4.246M |
| March 31, 2015 | -2.956M |
| December 31, 2014 | -4.040M |
| September 30, 2014 | -4.094M |
| June 30, 2014 | -6.972M |
| March 31, 2014 | -5.267M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Johnson & Johnson | 210.00M |
| ANI Pharmaceuticals, Inc. | 23.00M |
| Corcept Therapeutics, Inc. | 124.49M |
| Veru, Inc. | -6.988M |
| Eli Lilly & Co. | 6.451B |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 0.1901M |
| Total Expenses (Quarterly) | 2.813M |
| EPS Diluted (Quarterly) | -0.3192 |
| Enterprise Value | -10.65M |
| Gross Profit Margin (Quarterly) | 92.32% |
| Profit Margin (Quarterly) | -1.38K% |
| Earnings Yield | -115.4% |
| Normalized Earnings Yield | -115.42 |